- Email: [email protected]
Speciality surfactants in demand
F O C U S
HEALTH CARE Discovery awarded European Patent covering proprietary peptides for humanized pulmonary surfactant technology Discovery Laboratories Inc announced the issuance of European Patent No 59006. The patent covers claims directed to compositions that contain the peptide KL4 (sinapultide) and related KL peptides for use as a therapeutic surfactant for treating respiratory distress syndrome and related conditions. Discovery Laboratories’ humanized surfactant technology platform and its lead product Surfaxin, are based on KL4’s proprietary peptide engineered to mimic human pulmonary surfactant. Discovery Laboratories Inc is a speciality pharmaceutical company leveraging its platform technology in humanized lung surfactants to develop novel respiratory therapies and pulmonary drug delivery products. Press release from: Discovery Laboratories Inc, 350, South Main Street, Suite 307, Doylestown, PA 18901, USA. Tel: +1 215 340 4699. Fax: 215 340 3940. Email: [email protected]. Website: http://www.discoverylabs.com (7 Oct 2002)
Discovery and CollaGenex collaborate to develop novel treatments for respiratory diseases Discovery Laboratories Inc and CollaGenex Pharmaceuticals Inc (CollaGenex) announced a research collaboration to evaluate the combination of their platform technologies for the development of novel respiratory disease therapeutics. The two companies will collaborate on the pre-clinical evaluation of an aerosolised formulation of Discovery Laboratories’ humanised lung surfactants combined with CollaGenex’s Impacs (Inhibitors of Multiple Proteases and CytokineS) compounds for the treatment of respiratory diseases. The objective of the collaboration will be to develop and assess formulations of humanised lung surfactant and protease inhibitors as potential treatments for diseases such as Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Chronic Interstitial Lung Disease and Acute Lung Injury. Discovery Laboratories Inc is a speciality 6
O N
S U R FA C TA N T S
pharmaceutical company leveraging its platform technology in humanised lung surfactants to develop potential novel respiratory therapies and pulmonary drug delivery products. Press release from: Discovery Laboratories Inc, 350, South Main Street, Suite 307, Doylestown, PA 18901, USA. Tel: +1 215 340 4699. Fax: +1 215 340 3940. E-mail: [email protected]. Website: http://www.discoverylabs.com (17 Oct 2002)
STATISTICS/ REVIEWS The changing face of the surfactant market After more than a decade of consolidation in the surfactants industry, fewer than a dozen global producers of primary surfactants remain, according to a new study by Colin A Houston & Associates Inc (CAHA). The restructuring of supply is an important factor, but the market is also having to contend with overcapacity issues, new surfactants being developed, the increasing impact of environmental regulation, and changes in the product value chain. The new study, Surfactant Developments – Forecast to 2010 devotes a 94-page chapter to the analysis of key issues facing the surfactant market. In West Europe, surfactant overcapacity has been a major issue, and little change is expected in the near future, since producers are very reluctant to shut down sulfation and ethoxylation plants. The situation is different in Asia, where nearly 50% of the 184 sulfation/sulfonation sites are integrated with detergent producers, and good market growth has supported their operations. Another developing issue is the availability of surfactant intermediates. After a period of tight supply, new capacity for detergent alcohols and linear alkylbenzene is threatening to create a surplus of intermediates and drive prices down. Detergent reformulations are already shifting some consumption from LABS to alcohol derivatives. Changes in the surfactant intermediates market will benefit some surfactant producers and negatively impact others. With few exceptions, surfactant producers are pursuing a higher degree of integration and are
adopting new marketing strategies in order to defend and expand their positions. CAHA’s study details the activities and strategic approach of individual companies through profiles of nine global surfactant producers and four regional ones. Worldwide consumption of surfactants is expected to grow at an average rate of 3%/y, from 10.5 M tons in 2000 to 14.3 M tons in 2010, according to CAHA. Latin America and Asia are the regions expected to have the highest surfactant growth rates. In addition to an overview of total surfactant consumption, the study details the markets for the five “primary” surfactants: linear alkylbenzene sulfonates (LABS), alcohol ethoxysulfates (AES), alcohol sulfates (AS), alcohol ethoxylate (AE), and alkylphenol ethoxylate (APE) by region and by end use. Press release from: Colin A Houston & Associates Inc, 20, Milltown Road, Suite 206, Brewster, NY 10509, USA. Tel: +1 845 279 7891. Fax: +1 845 279 7751. Website: http://www.colin-houston.com (8 Oct 2002)
More consolidation projected for surfactants market An extensive review of the global surfactants market, covering: global demand (11 M tonnes in 2002), products (linear alkylbenzene sulfonates, alcohol ether sulfates, alcohol sulfates, alkylphenol ethoxylates, and alcohol ethoxylates), demand growth forecasts, and major players (listed). Chemical Market Reporter, 30 Sep 2002 (Website: http://www.chemicalmarketreporter.com)
Speciality surfactants in demand The Freedonia Group’s Specialty Surfactants report foresees a 4.3%/y rise in demand for speciality surfactants, resulting in $3.6 bn, or £2.1 bn, in 2006. The personal care markets exhibit the larger demand segment, although industrial markets are trailing behind. The demand will be strengthened by biodegradability, milder products, naturally derived surfactants and surfactants for treated wipes. Cationic surfactants will grow 4%/y; anionic 4.1%/y; non-ionic 4.4%/y; amphoteric 5.9%/y, while other speciality surfactants will rise 4.9%/y. HAPPI, Household & Personal Products Industry, Oct 2002, 39 (10), 14
DECEMBER 2002
HEALTH CARE Discovery awarded European Patent covering proprietary peptides for humanized pulmonary surfactant technology Discovery Laboratories Inc announced the issuance of European Patent No 59006. The patent covers claims directed to compositions that contain the peptide KL4 (sinapultide) and related KL peptides for use as a therapeutic surfactant for treating respiratory distress syndrome and related conditions. Discovery Laboratories’ humanized surfactant technology platform and its lead product Surfaxin, are based on KL4’s proprietary peptide engineered to mimic human pulmonary surfactant. Discovery Laboratories Inc is a speciality pharmaceutical company leveraging its platform technology in humanized lung surfactants to develop novel respiratory therapies and pulmonary drug delivery products. Press release from: Discovery Laboratories Inc, 350, South Main Street, Suite 307, Doylestown, PA 18901, USA. Tel: +1 215 340 4699. Fax: 215 340 3940. Email: [email protected]. Website: http://www.discoverylabs.com (7 Oct 2002)
Discovery and CollaGenex collaborate to develop novel treatments for respiratory diseases Discovery Laboratories Inc and CollaGenex Pharmaceuticals Inc (CollaGenex) announced a research collaboration to evaluate the combination of their platform technologies for the development of novel respiratory disease therapeutics. The two companies will collaborate on the pre-clinical evaluation of an aerosolised formulation of Discovery Laboratories’ humanised lung surfactants combined with CollaGenex’s Impacs (Inhibitors of Multiple Proteases and CytokineS) compounds for the treatment of respiratory diseases. The objective of the collaboration will be to develop and assess formulations of humanised lung surfactant and protease inhibitors as potential treatments for diseases such as Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Chronic Interstitial Lung Disease and Acute Lung Injury. Discovery Laboratories Inc is a speciality 6
O N
S U R FA C TA N T S
pharmaceutical company leveraging its platform technology in humanised lung surfactants to develop potential novel respiratory therapies and pulmonary drug delivery products. Press release from: Discovery Laboratories Inc, 350, South Main Street, Suite 307, Doylestown, PA 18901, USA. Tel: +1 215 340 4699. Fax: +1 215 340 3940. E-mail: [email protected]. Website: http://www.discoverylabs.com (17 Oct 2002)
STATISTICS/ REVIEWS The changing face of the surfactant market After more than a decade of consolidation in the surfactants industry, fewer than a dozen global producers of primary surfactants remain, according to a new study by Colin A Houston & Associates Inc (CAHA). The restructuring of supply is an important factor, but the market is also having to contend with overcapacity issues, new surfactants being developed, the increasing impact of environmental regulation, and changes in the product value chain. The new study, Surfactant Developments – Forecast to 2010 devotes a 94-page chapter to the analysis of key issues facing the surfactant market. In West Europe, surfactant overcapacity has been a major issue, and little change is expected in the near future, since producers are very reluctant to shut down sulfation and ethoxylation plants. The situation is different in Asia, where nearly 50% of the 184 sulfation/sulfonation sites are integrated with detergent producers, and good market growth has supported their operations. Another developing issue is the availability of surfactant intermediates. After a period of tight supply, new capacity for detergent alcohols and linear alkylbenzene is threatening to create a surplus of intermediates and drive prices down. Detergent reformulations are already shifting some consumption from LABS to alcohol derivatives. Changes in the surfactant intermediates market will benefit some surfactant producers and negatively impact others. With few exceptions, surfactant producers are pursuing a higher degree of integration and are
adopting new marketing strategies in order to defend and expand their positions. CAHA’s study details the activities and strategic approach of individual companies through profiles of nine global surfactant producers and four regional ones. Worldwide consumption of surfactants is expected to grow at an average rate of 3%/y, from 10.5 M tons in 2000 to 14.3 M tons in 2010, according to CAHA. Latin America and Asia are the regions expected to have the highest surfactant growth rates. In addition to an overview of total surfactant consumption, the study details the markets for the five “primary” surfactants: linear alkylbenzene sulfonates (LABS), alcohol ethoxysulfates (AES), alcohol sulfates (AS), alcohol ethoxylate (AE), and alkylphenol ethoxylate (APE) by region and by end use. Press release from: Colin A Houston & Associates Inc, 20, Milltown Road, Suite 206, Brewster, NY 10509, USA. Tel: +1 845 279 7891. Fax: +1 845 279 7751. Website: http://www.colin-houston.com (8 Oct 2002)
More consolidation projected for surfactants market An extensive review of the global surfactants market, covering: global demand (11 M tonnes in 2002), products (linear alkylbenzene sulfonates, alcohol ether sulfates, alcohol sulfates, alkylphenol ethoxylates, and alcohol ethoxylates), demand growth forecasts, and major players (listed). Chemical Market Reporter, 30 Sep 2002 (Website: http://www.chemicalmarketreporter.com)
Speciality surfactants in demand The Freedonia Group’s Specialty Surfactants report foresees a 4.3%/y rise in demand for speciality surfactants, resulting in $3.6 bn, or £2.1 bn, in 2006. The personal care markets exhibit the larger demand segment, although industrial markets are trailing behind. The demand will be strengthened by biodegradability, milder products, naturally derived surfactants and surfactants for treated wipes. Cationic surfactants will grow 4%/y; anionic 4.1%/y; non-ionic 4.4%/y; amphoteric 5.9%/y, while other speciality surfactants will rise 4.9%/y. HAPPI, Household & Personal Products Industry, Oct 2002, 39 (10), 14
DECEMBER 2002